http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2187304-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_29cafee4010bf7b9bd2662b7f2eb4704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b8cf77b8e89e5fbdeaca0875e3bfbbf6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9af0167c7a64c4f6c795090697dbbd28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 |
| filingDate | 2000-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2002-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_683b7fbc5662fdebc016fb7107ef01c4 |
| publicationDate | 2002-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2187304-C2 |
| titleOfInvention | Method for treating primary failure of ileocecal valve |
| abstract | FIELD: medicine, gastroenterology. SUBSTANCE: the method deals with restoring a closing function of ileocecal valve due to treatment with magnesium orotate indicated perorally at the dosage of 1.0 g thrice daily for 3 months, then at the dosage of 0.5 g thrice daily for the period of the next 3 months. The method enables to conduct therapy at excluding the necessity of operative interference. EFFECT: higher efficiency of therapy. |
| priorityDate | 2000-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 27.